T. Ferguson

发表

Taxanes for adjuvant treatment of early breast cancer.

D. Ghersi, N. Wilcken, A. Nowak, 2007, The Cochrane database of systematic reviews.

Bisphosphonates for prevention of bone loss in women with early breast cancer

S. Verma, A. Cheung, K. Pritchard, 2009 .

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

V. Gebski, P. Gibbs, F. Lammert, 2018, Clinical colorectal cancer.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

T. Powles, T. Choueiri, S. Park, 2021 .

89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

A. Redfern, N. Lenzo, P. Viswambaram, 2022, BMJ Open.

A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial pro

I. Davis, A. Redfern, Dickon Hayne, 2021, BJU international.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

V. Gebski, P. Gibbs, V. Heinemann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Sub-urothelial durvalumab injection-1 (SUBDUE-1): A novel approach to immunotherapy for bladder cancer.

I. Davis, A. Redfern, P. Viswambaram, 2021 .

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

T. Powles, T. Choueiri, S. Park, 2022, Journal of Clinical Oncology.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy

R. Newton, S. Chambers, N. Hart, 2017, BMJ Open.

Which patients with renal cancer may benefit from sunitinib therapy?

M. Gore, T. Ferguson, 2010, Therapeutic advances in medical oncology.

Taxanes for adjuvant treatment of early breast cancer.

D. Ghersi, N. Wilcken, A. Nowak, 2019, The Cochrane database of systematic reviews.

1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Lacombe, C. Gedye, P. Tomczak, 2022, Annals of Oncology.

A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer (EBC)

D. Ghersi, N. Wilcken, A. Nowak, 2007 .

Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

T. Choueiri, S. Park, P. Tomczak, 2023, Journal of Clinical Oncology.

Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib.

J. Larkin, L. Pickering, M. Gore, 2010 .

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

M. Climent, L. Lacombe, Chung-Han Lee, 2023, The Lancet. Oncology.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

V. Gebski, P. Gibbs, V. Heinemann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

L. Lacombe, Chung-Han Lee, C. Gedye, 2023, Journal of Clinical Oncology.

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule.

I. Davis, A. Redfern, C. Hawks, 2022, Journal of Clinical Oncology.